{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:42:33Z","timestamp":1793745753277,"version":"4.6.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although antiretroviral therapy (ART) has become less toxic over time, its long-term adverse effects remain a concern. In ART-naive people, tenofovir alafenamide (TAF) is frequently prescribed to reduce the toxicity of tenofovir disoproxil fumarate (TDF). However, the metabolic impact of TAF remains a concern. This study aimed to evaluate the metabolic effects of TAF in ART-naive participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from the Cohort of the Spanish HIV Research Network (CoRIS). We included ART-naive participants who initiated either bictegravir\/emtricitabine\/TAF (BIC\/FTC\/TAF) or dolutegravir + lamivudine (DTG+ 3TC), matched by propensity score, after excluding those with hepatitis B. We compared changes in weight, metabolic biomarkers, and the incidence of metabolism-related clinical events over 96 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 340 participants were matched in each group. The median age was 34 years, 95% were male, and 62% were from Western Europe. The mean weight gain was 1.4\u2005kg (95% confidence interval [CI]: 1.1, 1.8) after 96 weeks, with no significant differences between the BIC\/FTC\/TAF and DTG + 3TC groups. Changes in body mass index, lipid levels, hepatic steatosis index, and incidence of clinical events (hypertension, diabetes mellitus, dyslipidemia, and liver steatosis) were also similar between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide cohort of ART-naive individuals, initiation of BIC\/FTC\/TAF or DTG + 3TC resulted in similar modest increases in weight and lipid levels after 96 weeks, with no significant differences in metabolic outcomes or clinical events. These findings suggest that the metabolic profile of TAF should not be a deciding factor when choosing between 2- and 3-drug ART regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae645","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T15:24:19Z","timestamp":1734794659000},"page":"263-270","source":"Crossref","is-referenced-by-count":19,"title":["Metabolic Complications After Initiating BIC\/FTC\/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-6528","authenticated-orcid":false,"given":"Alejandro G","family":"Garc\u00eda-Ruiz de Morales","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Medicine, University of Alcal\u00e1 , Alcal\u00e1 de Henares, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Su\u00e1rez Robles","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"P\u00e9rez-El\u00edas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8nia","family":"Negredo","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol , Badalona ,","place":["Spain"]},{"name":"Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"AIDS Immunopathogenesis Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Elena","family":"G\u00f3mez Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gonz\u00e1lez-Ruano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Infanta Sof\u00eda, FIIB HUIS HUHEN , Madrid ,","place":["Spain"]},{"name":"Department of Medicine, Universidad Europea , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Alberto","family":"de Z\u00e1rraga Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario San Agust\u00edn de Avil\u00e9s, Universidad de Oviedo, Oviedo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Due\u00f1as Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Unit, Hospital Cl\u00ednico Universitario de Valladolid, University of Valladolid , Valladolid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno Guill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Medicine, University of Alcal\u00e1 , Alcal\u00e1 de Henares, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-3908","authenticated-orcid":false,"given":"Javier","family":"Mart\u00ednez-Sanz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"2025091917000870500_ciae645-B1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2025091917000870500_ciae645-B2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV cohort study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"2025091917000870500_ciae645-B3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2025091917000870500_ciae645-B5","author":"EACS"},{"key":"2025091917000870500_ciae645-B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025091917000870500_ciae645-B7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091917000870500_ciae645-B8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/COH.0000000000000379","article-title":"Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide","volume":"12","author":"Gotham","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2025091917000870500_ciae645-B10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/cid\/ciy083","article-title":"Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine","volume":"67","author":"Glidden D","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091917000870500_ciae645-B13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2025091917000870500_ciae645-B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cid\/ciz439","article-title":"Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077","volume":"70","author":"Landovitz","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B15","doi-asserted-by":"crossref","first-page":"E652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B17","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025091917000870500_ciae645-B18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eimc.2011.06.002","article-title":"La cohorte de la red espa\u00f1ola de investigaci\u00f3n en sida y su biobanco: organizaci\u00f3n, principales resultados y p\u00e9rdidas al seguimiento","volume":"29","author":"Sobrino-Vegas","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025091917000870500_ciae645-B19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2025091917000870500_ciae645-B20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00394-018-1677-2","article-title":"Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children","volume":"58","author":"Bonafini","year":"2019","journal-title":"Eur J Nutr"},{"key":"2025091917000870500_ciae645-B21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/CEOR.S413800","article-title":"Weight and BMI changes following initiation of emtricitabine\/tenofovir alafenamide co-formulated with darunavir or co-administered with dolutegravir in overweight or obese, ART-na\u00efve people living with HIV-1","volume":"15","author":"Donga","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"2025091917000870500_ciae645-B22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/COH.0000000000000833","article-title":"Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV","volume":"19","author":"Capeau","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"key":"2025091917000870500_ciae645-B23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12981-023-00591-3","article-title":"Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-na\u00efve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study","volume":"21","author":"Mukuna","year":"2024","journal-title":"AIDS Res Ther"},{"key":"2025091917000870500_ciae645-B24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025091917000870500_ciae645-B25","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a US cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2025091917000870500_ciae645-B26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025091917000870500_ciae645-B27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-024-00604-9","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine in virologically suppressed people with HIV-1 aged \u2265 50 years: week 48 pooled results from the TANGO and SALSA studies","volume":"21","author":"Walmsley","year":"2024","journal-title":"AIDS Res Ther"},{"key":"2025091917000870500_ciae645-B28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B29","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2025091917000870500_ciae645-B30","author":"Ramgopal"},{"key":"2025091917000870500_ciae645-B31","author":"McComsey"},{"key":"2025091917000870500_ciae645-B32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B33","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"key":"2025091917000870500_ciae645-B34","first-page":"990","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV","volume":"79","author":"Damas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/cid\/ciad286","article-title":"Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy","volume":"77","author":"Surial","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025091917000870500_ciae645-B36","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/S2352-3018(23)00233-3","article-title":"Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL collaboration and the antiretroviral therapy cohort collaboration","volume":"10","author":"Rein","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae645\/62799556\/ciae645.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/263\/62799556\/ciae645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/263\/62799556\/ciae645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:00:16Z","timestamp":1758315616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/2\/263\/8099223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,28]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae645","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,3,28]]}}}